SRR8943000
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.350
- TGF_BETA_SIGNALING+0.350
- ANGIOGENESIS+0.330
- PANCREAS_BETA_CELLS+0.330
- UV_RESPONSE_DN+0.330
- KRAS_SIGNALING_DN+0.240
- ESTROGEN_RESPONSE_EARLY+0.190
- HEME_METABOLISM+0.190
- WNT_BETA_CATENIN_SIGNALING+0.170
- APOPTOSIS+0.150
Top 10 suppressed
- E2F_TARGETS-0.660
- G2M_CHECKPOINT-0.550
- MYC_TARGETS_V2-0.530
- MYC_TARGETS_V1-0.300
- UNFOLDED_PROTEIN_RESPONSE-0.300
- IL6_JAK_STAT3_SIGNALING-0.260
- MTORC1_SIGNALING-0.250
- MITOTIC_SPINDLE-0.240
- PI3K_AKT_MTOR_SIGNALING-0.240
- DNA_REPAIR-0.230
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-BH-A0HP-01A-12R-A084-07 | — | A | 0.837 |
| 2 | TCGA-50-5944-01A-11R-1755-07 | — | cohortA1 | 0.807 |
| 3 | f8877925-49e4-420e-8bd8-cac3a47b67d1 | — | — | 0.805 |
| 4 | TCGA-AN-A0FS-01A-11R-A034-07 | — | A | 0.802 |
| 5 | TCGA-56-7822-01A-11R-2125-07 | — | cohortSQ1 | 0.801 |
| 6 | MNG356 | — | — | 0.795 |
| 7 | GSM5359413 | — | — | 0.791 |
| 8 | sclcCHTN02019_S70.txt | — | cohortSC | 0.788 |
| 9 | TCGA-GD-A3OP-01A-21R-A220-07 | — | — | 0.779 |
| 10 | TCGA-CR-7389-01A-11R-2016-07 | — | — | 0.778 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.350 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.350 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.330 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.330 | Cobimetinib | — uncovered |
| UV_RESPONSE_DN | 0.330 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.240 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.190 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.190 | Temsirolimus | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.170 | Inavolisib | — uncovered |
| APOPTOSIS | 0.150 | Idelalisib | — uncovered |
| COMPLEMENT | 0.150 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.150 | Inavolisib | — uncovered |
| COAGULATION | 0.140 | Binimetinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.140 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.130 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.120 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.110 | Inavolisib | — uncovered |
| MYOGENESIS | 0.110 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.100 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.080 | Inavolisib | — uncovered |